At least in neuroblastoma, where patients are typically stratified into risk groups based on multiple parameters, MYCN amplification (MNA) represents the most relevant and independent negative prognostic factor allowing straightforward patient classification into the high-risk group21–23. Here, MYCN is linked to neuroblastoma.